DarwinHealth is a precision-focused cancer medicine company, utilising systems-biology derived algorithms to identify appropriate therapies for cancer patients and to systematically discover and prioritize the next generation of immunogenic, tumor-specific antigens.
Under the terms of the agreement, DarwinHealth will utilize a combined single-cell transcriptome analysis and bioinformatics-based approach using both mouse and human cancerous and non-cancerous tissues to identify the next generation of shared "off-the-shelf" tumor-specific antigens.
Hookipa will perform the validation experiments and be granted exclusive rights to the development, manufacturing and commercialization of products arising from the collaboration.
Hookipa Pharma is a clinical stage biopharmaceutical company developing a new class of immuno-therapeutics targeting infectious diseases and cancers based on its proprietary technology platform that is designed to reprogram the body's immune system.
Its proprietary arenavirus-based technologies, Vaxwave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce potent antigen specific CD8+ T cells and pathogen-neutralizing antibodies.
Both, Vaxwave and TheraT, are designed to allow for repeat administration while maintaining an immune response.
TheraT has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. Our "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.
The company has successfully completed a Phase 1 trial of a Vaxwave-based prophylactic vaccine to protect against cytomegalovirus infections. It has initiated enrollment for a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
To expand its infectious disease portfolio, the company as forged a partnership with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. The company is building a proprietary immuno-oncology pipeline by targeting TheraT towards virally mediated cancer antigens, self-antigens and next-generation antigens.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer